Next, accordingly to the strong inhibition of tumor growth, immunoblotting analyses performed on lysates from treated tumors showed a marked inhibition of Akt and ERK1/2 pathways, downstream of both PDGFRβ [22, 31, 35] and oncogenic PD-L1 [40, 55], in the tumors from mice treated with the aptamer, antibody and their combination (Fig. 4d). Here, AKT1 is linked to neoplasm.